Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Valeritas to Release Second Quarter 2017 Financial Results and Host Conference Call on Friday, August 11, 2017

Posted on: 27 Jul 17

BRIDGEWATER, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Valeritas Holdings, Inc. (NASDAQ:VLRX) today announced that it will release its second quarter 2017 financial results on Friday, August 11, 2017, before market open.

Valeritas will hold a conference call on Friday, August 11, 2017, at 11:00 a.m. EDT to discuss the results. The dial-in numbers are (833) 235-7647 for domestic callers and (647) 689-4168 for international callers. The conference ID number is 56805537. A live webcast of the conference call will be available on the investor relations page of the Valeritas corporate website at

If you are unable to participate during the live webcast, a replay will remain available until Valeritas reports its third quarter 2017 financial results on the investor relations page of the Valeritas corporate website at In addition, a telephonic replay of the call will be available through August 12, 2017. The replay dial-in numbers are (800) 585-8367 for domestic callers and (416) 621-4642 for international callers.  Please use the replay pin number 56805537.

About Valeritas, Inc.
Valeritas is a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies.  Valeritas’ flagship product, V-Go® Wearable Insulin Delivery device, is a simple, wearable, basal-bolus insulin delivery solution for patients with Type 2 diabetes that enables patients to administer a continuous preset basal rate of insulin over 24 hours. It also provides on-demand bolus dosing at mealtimes. It is the only basal-bolus insulin delivery device on the market today specifically designed keeping in mind the needs of type 2 diabetes patients. Headquartered in Bridgewater, New Jersey, Valeritas operates its R&D functions in Shrewsbury, Massachusetts. For more information, please visit


Last updated on: 28/07/2017

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.